HomeAI · summaries
Storia in 4 fonti
Biogen, Eisai announce new data on efficacy, safety of LEQEMBI SC-AI
Eisai (ESAIY) and Biogen (BIIB) announced that new data presented at the Alzheimer’s Association International Conference, AAIC, 2026 in London ...
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Subcutaneous, intravenous outcomes with lecanemab comparable in Alzheimer’s disease
Outcomes following subcutaneous and intravenous treatment with lecanemab for Alzheimer’s disease were comparable, according to a group of abstracts presented at the Alzheimer’s…
- ·
markets.businessinsider.com
Biogen, Eisai announce new data on efficacy, safety of LEQEMBI SC-AI
Eisai (ESAIY) and Biogen (BIIB) announced that new data presented at the Alzheimer’s Association International Conference, AAIC, 2026 in London ...
